Teduglutide

From Wikipedia, the free encyclopedia
Teduglutide
Systematic (IUPAC) name
L-histidylglycyl-L-α-aspartylglycyl-L-seryl-L-phenylalanyl-L-seryl-L-α-aspartyl-L-α-glutamyl-L-methionyl-L-asparaginyl-L-threonyl-L-isoleucyl-L-leucyl-L-α-aspartyl-L-asparaginyl-L-leucyl-L-alanyl-L-alanyl-L-arginyl-L-α-aspartyl-L-phenylalanyl-L-isoleucyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-isoleucyl-L-glutaminyl-L-threonyl-L-lysyl-L-isoleucyl-L-threonyl-L-aspartic acid
Clinical data
Trade names Gattex, Revestive
Legal status ?
Routes Subcutaneous injection
Pharmacokinetic data
Half-life 2 h
Identifiers
CAS number 197922-42-2
ATC code A16AX08
PubChem CID 16139605
KEGG D06053 YesY
ChEBI CHEBI:72305 YesY
Chemical data
Formula C164H252N44O55S 
Mol. mass 3752.082 g/mol
 YesY (what is this?)  (verify)

Teduglutide (brand names Gattex and Revestive) is a 36-membered polypeptide and glucagon-like peptide-2 analog that is used for the treatment of short bowel syndrome. It works by promoting mucosal growth and possibly restoring gastric emptying and secretion.[1] In Europe it is marketed under the brand Revestive by Nycomed. It was approved by the United States under the name Gattex on December 21, 2012.

References

This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.